 Response to treatment based on clinical data or structural imaging, usually requires several chemotherapeutic cycles to establish degree of effectiveness 5. Lately, FDG-PETCT has been used in different types of neoplasms, breast cancer among them, to establish early response to treatment 6,7. Recent data has established the usefulness of metabolic analysis via FDG-PET, in separating subgroups of chemotherapy. For such analytical approach, sequential estimation of SUVs Standardized Uptake Value have been measured along the duration of the treatment. Reduction in SUVs presumes adequate response to treatment 8, while little or no change in metabolic activity presumes sub-optimal response . 